HCC → FXR−/− → Increased levels of BAs → Activate STAT3 → Increased expression of BCL-2 and MCL-1 → Reduced the pro-apoptotic effects of sorafenib → HCC drug resistance. The gene discussed is MCL1; the disease is hepatocellular carcinoma.